|
Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate for the treatment of cancers.〔(Statement On A Nonproprietary Name Adopted By The Usan Council - Inotuzumab ozogamicin ), ''American Medical Association''.〕 It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name). This drug is being developed by Pfizer and UCB. It is undergoing numerous clinical trials,〔http://clinicaltrials.gov/ct2/results?term=Inotuzumab+ozogamicin〕 including two phase II trials for Non-Hodgkin lymphoma (NHL). A phase III trial in patients with follicular b-cell NHL has been terminated due to poor enrollment.〔(Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) )〕 A Phase III trial in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who were not candidates for intensive high-dose chemotherapy was terminated for futility.〔http://pfizer.newshq.businesswire.com/press-release/pfizer-discontinues-phase-3-study-inotuzumab-ozogamicin-relapsed-or-refractory-aggress〕 ==See also== * Gemtuzumab ozogamicin * Antibody-drug conjugate 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Inotuzumab ozogamicin」の詳細全文を読む スポンサード リンク
|